Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Estimated
~$10 – $8,750
TORL Biotherapeutics, LLCNCT07439653
Phase 2
PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin l…
Relapsed or Refractory B-cell Non-Hodgkin LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
Estimated
~$10 – $6,250
University of UtahNCT06300528